Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.
Moehler M, Ryu MH, Dvorkin M, Lee KW, Coşkun HŞ, Wong R, Chung HC, Poltoratsky A, Tsuji A, Yen CJ, Muntean AS, Le Sourd S, Vaccaro GM, Overton L, Boku N, Wainberg ZA, Patel M, Sharma M, Xiong H, Conti I, Taieb J, Bang YJ. Moehler M, et al. Among authors: vaccaro gm. Future Oncol. 2019 Feb;15(6):567-577. doi: 10.2217/fon-2018-0668. Epub 2018 Oct 31. Future Oncol. 2019. PMID: 30379568 Free article. Clinical Trial.
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.
Moehler M, Dvorkin M, Boku N, Özgüroğlu M, Ryu MH, Muntean AS, Lonardi S, Nechaeva M, Bragagnoli AC, Coşkun HS, Cubillo Gracian A, Takano T, Wong R, Safran H, Vaccaro GM, Wainberg ZA, Silver MR, Xiong H, Hong J, Taieb J, Bang YJ. Moehler M, et al. Among authors: vaccaro gm. J Clin Oncol. 2021 Mar 20;39(9):966-977. doi: 10.1200/JCO.20.00892. Epub 2020 Nov 16. J Clin Oncol. 2021. PMID: 33197226 Free PMC article. Clinical Trial.
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZH, Marinello P, Diaz LA Jr; KEYNOTE-177 Investigators. André T, et al. N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699. N Engl J Med. 2020. PMID: 33264544 Free article. Clinical Trial.
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).
Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, Lim HJ, Hezel AF, Vaccaro GM, Blanke CD. Ramanathan RK, et al. Among authors: vaccaro gm. Cancer. 2015 Jul 1;121(13):2193-7. doi: 10.1002/cncr.29363. Epub 2015 Mar 30. Cancer. 2015. PMID: 25827820 Free PMC article. Clinical Trial.
Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N, Shukla R, Elliott DA, Mitin T, Vaccaro GM, Dolan JP, Maggiore RJ, Schipper PH, Hunter JG, Thomas CR Jr, Holland JM. Nabavizadeh N, et al. Among authors: vaccaro gm. Dis Esophagus. 2016 Aug;29(6):614-20. doi: 10.1111/dote.12377. Epub 2015 Jun 5. Dis Esophagus. 2016. PMID: 26043837
Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR, Hart KD, Nabavizadeh N, Bensch KG, Vaccaro GM, Thomas CR Jr, Schipper PH, Hunter JG, Dolan JP. Haisley KR, et al. Among authors: vaccaro gm. Dis Esophagus. 2017 Jul 1;30(7):1-7. doi: 10.1093/dote/dox015. Dis Esophagus. 2017. PMID: 28475724
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Zhu AX, et al. Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Lancet Oncol. 2018. PMID: 29875066 Clinical Trial.
33 results